Search
for
Sort by
Research 30 of 783
- A comparative analysis of immune privilege in pregnancy and cancer in the context of checkpoint blockade immunotherapy
- Sintilimab-induced Alopecia Universalis in a Patient With the Anti-tumor Effect of Complete Remission After Hepatectomy
- Immune Microenvironment of Hair Follicles in Tumor Immunotherapy
- Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Alopecia and hair repigmentation associated with anti-programmed death-ligand 1 (PD-L1) immunotherapy
- The role of lymphocytes in the development and treatment of alopecia areata
- Diagnosis and treatment of cutaneous adverse effects of targeted therapy, antibody–drug conjugates, and immunotherapy in cancer patients: a national consensus statement by the Spanish Society of Medical Oncology and the Spanish Academy of Dermatology and Venereology
- Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies
- Cutaneous Toxicities of Advanced Treatment for Cutaneous Melanoma: A Prospective Study from a Single-Center Institution
- Nanomedicine-based immunotherapy for tissue regeneration
- Folate receptor β performs an immune checkpoint function in activated macrophages
- Where is the data? Delayed and chronic irAE surveillance and management after cessation of ICIs: expert insights from SITC on survivorship care and the need for long-term data
- Merkel cell carcinoma: updates in tumor biology, emerging therapies, and preclinical models
- Tregs: Where We Are and What Comes Next?
- Skin toxicity induced by chemotherapy or molecular targeted therapy combined with immune checkpoint inhibitors in Asian patients: A literature review by the Japanese Pharmacist-led Oncodermatology Study Team
- TCL1 transgenic mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic lymphocytic leukemia
- An In Situ Chemotherapy Drug Combined with Immune Checkpoint Inhibitor for Chemoimmunotherapy
- Cutaneous manifestations associated with immune checkpoint inhibitors
- N6-methyladenosine RNA Methylation Correlates with Immune Microenvironment and Immunotherapy Response of Melanoma
- Use of Contact Immunotherapy in the Treatment of Skin Diseases Other than Alopecia Areata
- Cellular therapeutics and immunotherapies in wound healing – on the pulse of time?
- Responsive Microneedles as a New Platform for Precision Immunotherapy
- SOCS1 and SOCS3 as key checkpoint molecules in the immune responses associated to skin inflammation and malignant transformation
- Anti-programmed cell death protein 1-induced lichenoid changes of the nail unit: Histopathologic description
- Cutaneous toxicity as a predictive biomarker for clinical outcome in patients receiving anticancer therapy
- Nivolumab-Induced Alopecia Areata: A Case Report and Literature Review
- Treatment Strategies for Cutaneous and Oral Mucosal Side Effects of Oncological Treatment in Breast Cancer: A Comprehensive Review
- Exploiting Unique Features of Microneedles to Modulate Immunity
- What's new in the pathogeneses and triggering factors of bullous pemphigoid